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Abstract
Introduction: Ankylosing spondylitis (AS) is characterized by abnormal bone formation in the spine and the
sacroiliac joints. In vitro assays demonstrate that carbonic anhydrase I (CA1) promotes calcium precipitation. This
study investigated the function of CA1 for bio-mineralization and determined if common polymorphisms in the
CA1 gene might contribute to AS risk.
Methods: Calcification was induced in Saos-2 cells, a human osteosarcoma cell line, with ascorbic acid and
b-glycerophosphate. Calcification was determined by Alizarin Red-S (AR-S) staining. Expressions of CA1, alkaline
phosphatase (ALP), bone sialoprotein (BSP), osteocalcin (OCN), osterix (OSX) and runt-related transcription factor-2
(Runx2) were determined by real-time PCR and western blotting. The cells were also treated with acetazolamide,
an anti-carbonic anhydrase drug. Genotyping was performed using Illumina VeraCode microarray in a case-control
study including 51 AS patients, 267 rheumatoid arthritis (RA) patients and 160 healthy controls. The result was
confirmed by Taqman assay, including 258 AS patients, 288 RA patients and 288 healthy controls.
Results: Following the induction of calcification, Saos-2 cells produced large amounts of calcium-rich deposits.
Increased transcriptions of CA1, ALP, BSP, OCN, OSX and Runx2, essential genes for ossification, were detected in
the cultured cells. Following treatmen with acetazolamide, the expression of CA1 obviously declined and
mineralized nodule formation was also decreased. Illumina microarray indicates that SNP at rs7841425 also showed
significant differences in allelic frequency (P = 0.01396) and genotypic frequency (P = 0.005902) between AS cases
and controls. In addition, SNP at rs7827474 showed significant differences in allelic frequency (P = 5.83E-04) and
genotypic frequency (P = 0.000186) between RA cases and controls (P values were adjusted to multiple
comparisons). The Taqman assay revealed that rs725605 demonstrated statistically significant evidence of allele
frequency (P = 0.022307) and gene frequency (P = 0.007731) for association with AS. This SNP did not show
significant differences in allelic frequencies and gene frequencies between RA patients and controls.
Conclusions: CA1 may play an essential role in bio-mineralization and new bone formation. The gene encoding
CA1 is susceptible to AS.
Introduction
Abnormal new bone formation and bone resorption are
the most distinctive features of ankylosing spondylitis
(AS) [1-3]. Histopathological experiments demonstrated
that severe forms of AS significantly correlate with
villous chronic synovitis, including obliterating vasculitis,
fibrosclerosis, necrosis and calcification of disintegrated
synovial structures [4]. Using a proteomic approach, we
previously screened novel AS-specific proteins by simul-
taneously comparing the expression profiles of synovial
membranes from patients with AS, rheumatoid arthritis
(RA) and osteoarthritis (OA). The proteomic study
revealed significantly increased expression of carbonic
anhydrase I (CA1) in the synovial membrane of AS
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patients compared with those of RA and OA patients.
Immunohistochemistry and western blot analysis con-
firmed the above findings [5]. CA1 is a member of the
carbonic anhydrase (CA) family, which catalyzes the
reversible hydration and dehydration reactions of CO2/
H2CO3 [6]. In vitro assays demonstrated that CA1 not
only enhances the hydration reaction but also promotes
the formation of CaCO3 [7,8]. Calcium salt precipitation
is an important step in bone formation. Thus, the
increased CA1 expression in the synovium of AS patients
may lead to improper mineralization by accelerating cal-
cium salt deposition [5]. However, no direct data support
the involvement of CA1 in bio-mineralization and bone
formation in cells and tissues.
In this study, we selected Saos-2 cells as a convenient
model of osteoblastic mineralization to investigate how
CA1 is involved in bio-mineralization and ossification
in vivo. The cell line was induced with b-glyceropho-
sphate (b-GP) and ascorbic acid (AA). We determined
the process of calcification by examining the expression
of alkaline phosphatase (ALP), bone sialoprotein (BSP),
osteocalcin (OCN), osterix (OSX), and runt-related gene
2 (Runx2), protein markers for ossification. We also
investigated the expression of CA1 in the cultured cells.
Furthermore, we observed the calcification in the cultured
cells in the presence of acetazolamide, an anti-carbonic
anhydrase drug to CA1. In addition, we determined if
common polymorphisms in the CA1 encoding gene are
susceptible to AS in the Chinese population using the Illu-
mina GoldenGate assay and Taqman genotyping methods.
The genotyping was performed in a case-control study
using a cohort of patients with rheumatoid arthritis (RA)
and healthy individuals as controls. To our knowledge,
this is the first study to examine this potential association.
Methods
Cell culture and induction of bio-mineralization
Saos-2 cells were cultured in McCoy’s 5A medium
(Gibco, Grand Island, New York, USA) supplemented
with 100 U/ml penicillin, 100 mg/ml streptomycin
(Gibco) and 15% (v/v) fetal bovine serum (Gibco). The
cells were cultured either in basic cell culture medium
or in osteogenic medium (OM) supplemented with
50 mg/ml AA (Sigma-Aldrich, St. Louis, Missouri, USA)
and 7.5 mM b-GP (Sigma). The protocol was based on
the study by Thouverey [9].
Alizarin Red-S staining and quantifying bio-mineralization
Cell cultures were washed with Phosphate buffered saline
buffer (PBS) and stained with 0.5% (w/v) Alizarin Red-S
(Sigma-Aldrich ) in PBS (pH = 5.0) for 30 minutes at
room temperature. After washing four times with PBS,
the stained cells were photographed. The cultured cells
were then de-stained with 10% (w/v) cetylpyridinium
chloride (Sigma-Aldrich, ) in PBS (pH = 7.0) for 60 min-
utes at room temperature. The AR-S concentration was
determined by measuring the absorbance at 562 nm. The
protocol was based on previously published studies
[9-11].
The effects of acetazolamide on bio-mineralization
To verify the effect of CA1 expression on bio-mineraliza-
tion, acetazolamide, a chemical inhibitor of CA, was used
to treat Saos-2 cells. Acetazolamide (Sigma) was dissolved
in dimethyl sulfoxide (DMSO, Solabio) at a concentration
of 0.05% and was added to cell cultures that were grown
to 70% confluence in OM. The cultures were grown in the
presence of acetazolamide at a final concentration of
100 μM for nine days. Saos-2 cells were also cultured in
OM with 0.05% DMSO as a control. The protocol was
based on a study by Hall et al. [12].
Cell proliferation assay
To evaluate the proliferative capacity of Saos-2 cells in
OM or in the presence of acetazolamide, the cells were
seeded onto 96-well culture plates and incubated until
they reached 70% confluence. The cultures were then
incubated with OM in the presence of 10 μM, 100 μM or
1 mM acetazolamide for three, six and nine days. Cell
proliferation was assessed using the MTT (3-(4, 5-
dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bro-
mide) assay. Aliquots of 20 μl of MTT reagent of MTT
Cell Proliferation Assay Kit (ATCC, Manassas, Virginia,
USA) at a concentration of 5 mg/ml were added to the
cell cultures. After four hours of treatment, 150 μl of
DMSO was added to the culture and slightly mixed for
10 minutes. The absorbance was measured at 490 nm
with a spectrophotometer.
RNA isolation and real-time PCR
Total RNA was extracted from the cultured Saos-2 cells
using a total RNA Isolation Kit (Omega Bio-Tek, Nor-
cross, Georgia, USA) according to the protocol of the
manufacturer. Concentrations of total RNA were deter-
mined with a spectrophotometer. The cDNA was pre-
pared with 500 ng of total RNA from each sample using
oligo-dT primers and the PrimeScriptTM RT-PCR Kit
(TaKaRa, Ostsu, Shiga, Japan). A quantitative PCR analysis
was performed with a LightCycler 480 thermocycler
(Roche, Basel, Switzerland.). Taqman real-time PCR was
conducted in 10 μl reaction mixtures containing 5 μl of
SYBR Green (ToYoBo, Osaka, Japan), 1 μl of each primer,
1 μl of cDNA and 2 μl of H2O. The optimized thermal
cycling program was as follows: step one, 95ºC for 180 sec-
onds; step two, 95ºC for 10 seconds, 59ºC for 10 seconds
and 72ºC for 25 seconds (45 cycles); and step three, a
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melting curve analysis from 59°C to 95ºC in 0.5ºC incre-
ments. The specificity of the individual amplification reac-
tions was assessed by examining the melting curves to
confirm the presence of a single gene-specific peak with
the characteristic melting temperature of the expected
product. The primers for ALP, BSP, OCN, OSX, Runx2
and CA1 are listed in Table 1. The PCR results were stan-
dardized to the level of glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) expression. For each sample, two
reactions were performed at the same time. One reaction
was performed to determine the mRNA level of the target
gene and the second reaction was performed to determine
the level of GAPDH. The experiment was performed in
triplicate and the PCR products were confirmed by a melt-
ing curve analysis. The relative expression of mRNA was
calculated using the comparative threshold cycle (Ct)
method according to the following formula: Ratio = 2-
ΔΔCt = 2ΔCt (sample), where ΔCt = Ct of target genes-Ct
of the endogenous control gene (GAPDH). The relative
target gene expression was normalized in comparison to
the GAPDH mRNA. The copy numbers of the targeted
mRNA in the samples were calculated automatically by
the data analysis software. Levels of the transcripts are
expressed as the median and range. Statistical differences
were assessed using the Mann-Whitney U-test; P <0.05
was considered statistically significant.
Western blot analysis
Cultured cells and animal tissues were homogenized in
RIPA buffer (Beyotime, Shanghai, China) supplemented
with protease and phosphatase inhibitors on ice and cen-
trifuged at 16000 × g for five minutes at 4°C. The superna-
tant was collected and the protein concentration was
determined using a BCA Protein Assay Kit (Beyotime).
Thirty micrograms of total protein were separated on a
12% SDS-polyacrylamide gel and transferred onto a PVDF
membrane. The membrane was rinsed with wash solution
and incubated with anti-human CA1 antibody (Santa
Cruz, Santa Cruz, California, USA) at a dilution of 1:500
overnight at 4°C. The antibody was prepared by immuniz-
ing a mouse with a peptide comprising CA1 amino acids
33 to 80, which are mapped near the N-terminus. The
manufacturer confirmed no cross-reactivity with other
carbonic anhydrases. Immunosignals were visualized with
a Protein Detector BCIP/NBT Western Blotting Kit (Beyo-
time) following the manufacturer’s instructions. The quan-
tification was conducted using ImageQuant 5.2 software.
A separate membrane prepared in the same manner was
probed with an anti-GAPDH antibody (Santa Cruz) to
normalize the sample loading.
Sample preparation and genomic DNA isolation
Peripheral blood samples were collected from patients
with RA and AS. The diagnosis of RA was made according
to the criteria of the American College of Rheumatology
[13]. The RA patients had high levels of C-reactive protein
(30 to 100 mg/L, mean 24 mg/L), anti-cyclic citrullinated
protein antibodies (anti-CCP; 300 to 3,000 U/ml) and
rheumatoid factor (RF; 160 to 2,560 U/ml). AS patients
had an average disease duration of seven years and were
positive for HLA-B27 antigen. Their symptoms were con-
sistent with the modified New York criteria for AS.
Patients were selected from the same population living in
the Shandong area of Northern China. They did not have
any personal or family history of serious illness. Control
individuals were from the same geographical area. Both
patients and healthy controls gave their written consent to
participate in the study and to allow their biological sam-
ples to be genetically analyzed. The Ethical Committee of
the Shandong Academy of Medicinal Sciences approved
this study.
Blood samples were put into Monovette tubes contain-
ing 3.8% sodium citrate. Genomic DNA was extracted
from whole blood samples with the Omega E-Z 96 Blood
DNA kit (Omega) according to the manufacturer’s proto-
col. DNA samples were dissolved in deionized water. The
concentration and quality of DNA samples were measured
using a spectrophotometer at 260 nm (A260) and 280 nm
(A280). An A260/A280 ratio of 1.7 to 1.9 was considered
to be highly pure DNA. Electrophoresis was also used to
examine the quality and integrity of DNA.
SNP selection and genotyping
Tag SNPs across the CA1 were determined by searching
the HapMap database. The tag SNPs were selected on the
basis of linkage disequilibrium patterns observed in the
Han Chinese in Beijing (CHB) samples that were geno-
typed as a part of the International HapMap Project. Only
SNPs with a minor allele frequency of greater than 5%
with a pair-wise r2 ≥ 0.8 in the HapMap were considered.
SNPs that were in exons and UTRs, as well as promoters
and introns within 500 bp of exons were also selected.
Candidate SNPs were submitted to Illumina for a design
score. The Illumina Assay Design Tool filtered out SNPs
that were not suitable for the Illumina platform. Finally,
Table 1 The primer sequences for real-time PCR.
gene Forward and Reverse Primers
ALP 5’-TGGACCTCGTTGACACC-3’ 5’-TCCTGTTCAGCTCGTACT -3’
BSP 5’-ATACAGGGTTAGCTGCAATC-3’
5’- TCCATTGTCTCCTCCGC -3’
OCN 5’-GGCGCTACCTGTATCAATG-3’ 5’-AGAGCGACACCCTAGAC -3’
OSX 5’-CCACCTACCCATCTGACT-3’ 5’-GTTTGGCTCCACCACTC -3’
Runx2 5’-TATTGGTCCTAAGGGAGACATC-3’ 5’-
TAAAGCGAATGGGCATGTT -3’
CA1 5’-GCTACAGGCTCTTTCAGTT-3’ 5’-GACTCCATCCACTGTATGTT -3’
GAPDH 5’-ACCACAGTCCATGCCATCAC-3’ 5’-TCCACCACCCTGTTGCTGTA -3’
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thirteen SNPs with a design score of ‘1’ were selected; they
span 23,000 bases of the chromosome. These SNPs
included one tagSNP, one coding SNP, one SNP at the
5’UTR, nine SNPs in the introns and one SNP in the pro-
moter region. These SNP sites and locations are described
in Table 2.
We performed genotyping using a custom-designed Illu-
mina 96-SNP VeraCode microarray (Illumina). Peripheral
blood samples were collected from patients with RA (n =
266, 183 women) and AS (n = 51, 10 women). RA patients
had a mean age of 51.7 years, while AS patients had a
mean age of 35.9 years. A total of 163 (60 women) healthy
individuals with a mean age of 48.0 years were blood
donors. Blood samples were put into Monovette tubes
containing 3.8% sodium citrate. The genotyping was con-
ducted with the BeadXpress Reader using the Illumina
VeraCode GoldenGate Assay kit. A total of 500 ng of
sample DNA were used per assay. Genotype clustering
and calling were performed using BeadStudio software
(Illumina). This work was completed at the Beijing Insti-
tute of Genomics.
To confirm the above results, tag SNP rs725605 was
genotyped using TaqMan SNP assays in a cohort of
288 patients with RA (209 women), 258 patients with
AS (85 women) and 288 healthy controls (132
women). These people are different than the people
used in the experiments of Illumina microarray assay.
RA patients had a mean age of 52.2 years, AS patients
had a mean age of 31.6 years and the healthy indivi-
duals had a mean age of 63.5 years. Assays were run
on a LightCycler II 480 Instrument (Roche) and evalu-
ated according to the manufacturer’s instructions.
Reactions were carried out in a total volume of 10 μl
using the following amplification protocol: denatura-
tion at 95°C for 10 minutes, followed by 40 cycles of
denaturation at 92°C for 15 seconds and finishing with
annealing and extension at 60°C for 1 minute. The
genotype of each sample was determined by measuring
allele-specific fluorescence using SDS 2.3 software for
allelic discrimination (Roche). Duplicate samples and
negative controls were included to check the accuracy
of genotyping.
Genotyping quality was examined by a detailed quality
control procedure consisting of >95% successful call rate,
duplicate calling of genotypes, internal positive control
samples and Hardy-Weinberg Equilibrium (HWE) testing.
SNPs were analyzed for association by comparing the
MAF (Minor Allele Frequency) between cases and con-
trols. Dominant and recessive models were considered
with respect to the minor allele. Associations of SNPs with
the diseases were evaluated using odds ratios (OR) with
95% confidence intervals (CI). Fisher’s exact test was used
for comparison between categorical variables. P values less
than 0.05 were considered statistically significant. Genoty-
pic associations were assessed using software Plink v1.07
and SHEsis [14,15]. Multiple-test correction including
genomic-control correction, Bonferroni single-step correc-
tion, Holm step-down correction and Sidak single-step
correction were performed by Plink v1.07. Linkage disequ-
librium (LD), coefficient (D’ and r2) and haplotype were
estimated by software Haploview 4.2 [14].
Statistical analyses
Statistical analyses of the data were performed using
SPSS V.16 software (SPSS, Chicago, Illinois, USA). The
multiple comparisons were conducted using analysis of
variance (ANOVA). T-test was used to assess statistical
differences of two groups. P values less than 0.05 were
considered significant.
Results
Bio-mineralization in Saos-2 cells incubated with OM
and acetazolamide
A large amount of calcium deposits was observed in the
cultured cells when the incubation was conducted in
OM for six and nine days (Figure 1A). The absorbance
of cetylpyridinium chloride was 3.46-fold higher in
Saos-2 cells that were incubated with OM than in the
cells that were cultured without induction for six days
(P = 4.63*10-5). The absorbance was 4.06-fold higher
after nine days than that of the control (P = 3.92*10-7)
(Figure 1B). The formation of calcium nodules was sig-
nificantly decreased in Saos-2 cells when acetazolamide
was included in the OM compared with the cells that
were stimulated with OM alone (Figure 1A). The absor-
bance of cetylpyridinium chloride was also considerably
decreased by 1.28-fold in Saos-2 cells that were treated
with acetazolamide for three days (P = 0.0003), 1.36-fold
after six days (P = 0.0008) and 1.26-fold after nine days
(P = 0.0001) when compared with cells that were cul-
tured with OM alone (Figure 1B).
Table 2 SNP information.
SNP ID chr position function allele amino acid
rs7827474 86241688 intron C/G
rs3808540 86244170 intron C/T
rs11774422 86244588 intron A/G
rs7011926 86245233 intron A/G
rs34456327 86245492 intron -/G
rs7821248 86245776 missense A Glu [E]
rs13276893 86250947 intron C/T
rs2220972 86253296 intron A/G
rs34282382 86264002 5’ UTR -/G
rs7840971 86264516 intron C/T
rs7841304 86264767 intron C/T
rs7818073 86264811 intron A/T
rs7841425 86264813 intron A/C
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Cell proliferation of Saos-2 cells incubated with OM and
acetazolamide
Saos-2 cells were incubated with OM in the absence or
presence of acetazolamide at concentrations of 10 μM,
100 μM and 1 mM for three, six and nine days. The
number of living cells was slightly increased in Saos-2
cells that were cultured in OM compared with the con-
trol group in normal medium for three, six and nine
days, but there were no significant changes between the
two cultures. The proliferation of Saos-2 cells was not
significantly different between cells that were incubated
with OM in the presence of 100 μM acetazolamide for
Figure 1 Measuring bio-mineralization in Saos-2 cells cultured with OM and acetazolamide (AZ). The Saos-2 cells were incubated with
normal medium, osteogenic medium (OM), and OM supplemented with 100 μM of AZ. A. The cell cultures were stained with AR-S to detect
calcium nodules and photographed at the original magnification and 100X magnification. B. The cell cultures were stained with cetylpyridinium
chloride and quantified by measuring its absorbance at 562 nm. This experiment was repeated three times. ** = P < 0.01, *** = P < 0.001.
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three days, six days and nine days. When Saos-2 cells
were incubated with OM in the presence of 1 mM acet-
azolamide, cell proliferation was significantly decreased
on the third day (P = 0.03), the sixth day (P = 0.023)
and the ninth day (P = 0.035) of the incubation when
compared with cells that were cultured with OM alone.
Therefore, 100 μM was considered to be the highest
non-toxic concentration of acetazolamide and was used
in the subsequent assays. The results are depicted in
Figure 2.
Expression of osteoblast-related genes and CA1 in Saos-2
cells during bio-mineralization
The mRNA level of Runx2 was 8.05-fold (P = 3.57*10-7)
higher in the stimulated cells than in cells without sti-
mulation, ALP increased 2.91-fold (P = 0.000929), BSP
increased 27.28-fold (P = 5.63*10-5), OCN increased
2.48-fold (P = 0.04) and OSX increased 1.8-fold (P =
0.002), when Saos-2 cells were incubated in OM for
nine days. After nine days of treatment with 100 μM
acetazolamide in OM, the expression levels of ALP
Figure 2 Measuring cell proliferation by the MTT assay. Saos-2 cells were incubated in (1) normal culture medium, (2) osteogenic medium,
(3) osteogenic medium supplemented with DMSO, and (4) osteogenic medium supplemented with 10 μM, 100 μM and 1 mM of acetazolamide
(AZ). The results of the MTT assay indicated that the cell proliferation was not significantly affected by osteogenic medium, DMSO or 100 μM AZ.
This experiment was repeated three times and similar results were obtained. The error bars represent the standard deviation from five replicate
measurements. DMSO, dimethyl sulfoxide; MTT, 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide; OM, osteogenic medium.
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(P = 8.71*10-5), BSP (P = 0.001), OCN (P = 0.007) and
Runx2 (P = 5.74*10-5) were significantly decreased in
Saos-2 cells compared to their levels in OM alone,
except for OSX (P = 0.026). These results are shown in
Figure 3.
The transcription (P = 0.007) and translation (P =
0.009) of CA1 in the stimulated cells were significantly
affected in a time-dependent manner for nine day’s cul-
ture compared with the controls. After treatment with
acetazolamide, CA1 transcription (P = 0.004) and trans-
lation (P = 0.012) were significantly decreased compared
with the cells cultured in OM alone. These results are
presented in Figure 4.
Single SNP analysis
We genotyped twenty-nine SNPs in the CA1 gene. All
SNPs yielded usable genotyping data and the study sample
success rate was 99% [See Additional file 1]. The Illumina
microarray data has been submitted to NCBI Gene
Expression Omnibus (GEO), a public functional genomics
data repository supporting MIAME-compliant data sub-
missions. The record was approved and assigned GEO
accession number (GSE39428). Differences in the allele
and genotype frequencies between cases and controls were
compared. Allelic frequency and genotype frequencies of
all SNPs were in Hardy-Weinberg equilibrium in controls.
SNP at rs34282382 showed significant differences in allelic
frequency and genotypic frequency in the AS cohort. SNP
at rs7841425 also showed significant differences in allelic
frequency and genotypic frequency between AS cases and
controls. Following multiple-test correction, rs7841425
still had a significant difference in allelic frequency and
genotypic frequency. In addition, SNP at rs7827474 had a
significant difference in allelic frequency and genotypic
Figure 3 Quantification of the expression of ALP, BSP, OCN, OSX and Runx2 by real-time PCR. Real-time PCR was used to measure the
mRNA levels of ALP, BSP, OCN, OSX and Runx2 mRNA in Saos-2 cells incubated with OM. The expression was normalized to the expression of
GAPDH. The results indicate that OM can stimulate transcription of these osteoblast-related genes in Saos-2 cells than in than cells without
stimulation. The also indicates that AZ can significantly decrease the expressions of these osteoblast-related genes except OSX in Saos-2 cells
compared to that in OM alone. This experiment was repeated three times and similar results were obtained. * = P < 0.05, ** = P < 0.01, *** = P
< 0.001. OM, osteogenic medium.
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Figure 4 Expression of CA1 in Saos-2 cells. The expression of CA1 in Saos-2 cells was determined by (A) western blotting and (B) real-time
PCR. The expression levels were normalized to the expression of GAPDH. The transcription and translation of CA1 were significantly increased in
Saos-2 cells cultured in the presence of OM, but decreased when the cells were incubated with 100 μM acetazolamide (AZ). This experiment
was repeated three times and similar results were obtained. * P < 0.05, ** = P < 0.01, *** = P < 0.001. OM, osteogenic medium.
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frequency between RA cases and controls. After multiple-
test correction, rs7827474 still had a significant difference
in allelic frequency and genotypic frequency between RA
cases and controls, indicating that the SNP is significantly
associated with an increased risk of RA. Other SNPs
located in the CA1 gene were not significantly different in
allelic or genotypic frequencies between the RA or AS
patients and controls. Tables 3 and 4 contain the allele fre-
quencies, genotype frequencies and the unadjusted and
adjusted P-values after the statistical analysis of these gen-
otyped SNPs. We also performed multivariate logistic
regression analysis using software Plink v1.07 to test the
correlations between the SNP and RA and AS. The P
values for rs7827474 and rs7841425 after logistic regres-
sion are also shown in Tables 3 and 4.
We performed additional genotyping for tag SNP
rs725605 in an independent case-control study using the
TaqMan method. Allelic frequencies and gene frequencies
of the SNP did not deviate from HWE in both cases and
the controls. The allele frequency and gene frequency for
SNP rs725605 demonstrated statistically significant evi-
dence for association with AS (P = 0.022307, OR (%95
CI) = 1.332797 (1.041573 to approximately 1.705446)).
The gene frequency for the SNPs also demonstrated statis-
tically significant evidence for association with AS (P =
0.007731). On the other hand, the SNPs rs725605 did not
show significant difference in allelic frequencies (P =
0.367743) and gene frequencies (P = 0.610868) between
RA patients and controls.
Discussion
AA and b-GP are commonly employed to stimulate
osteoblastic differentiation and induce in vivo mineraliza-
tion [16,17]. Following the stimulation of AA and b-GP,
a large amount of calcium-rich deposits was produced in
Saos-2 cells, while the transcription levels of osteogen-
esis-related genes, including ALP, BSP, OCN, OSX and
Runx2, were significantly increased. CA1 expression was





























rs7827474 C 1(0.010) 1(0.003) 0.395319 3.138614
(0.194542~50.636475)
G 101(0.990) 317(0.997)
CG 1(0.020) 1(0.006) 0.394186 0.943634 0.968272
GG 50(0.980) 158(0.994)
rs3808540* A 64(0.627) 196(0.613) 0.786888 1.065521
(0.672573~1.688048}
G 38(0.373) 124(0.388)
AA 19(0.373) 64(0.400) 0.475302 0.518298 0.185552
AG 26(0.510) 68(0.425)
GG 6(0.118) 28(0.175)
rs11774422 A 0(0.000) 1(0.003) 0.571929
G 102(1.000) 319(0.997)
AG 0(0.000) 1(0.006) 0.571472 1 0.968372
GG 51(1.000) 159(0.994)
rs34456327 A 98(1.000) 312(1.000)
AA 49(1.000) 156(1.000)
rs7821248 A 0(0.000) 1(0.003) 0.575955
G 98(1.000) 313(0.997)
AG 0(0.000) 1(0.006) 0.57549 1 0.968069
GG 49(1.000) 156(0.994)
rs13276893 A 69(0.704) 218(0.717) 0.804077 0.938627
(0.569058~1.548209)
G 29(0.296) 86(0.283)
AA 22(0.449) 77(0.507) 0.475953 0.116312 0.641532
AG 25(0.510) 64(0.421)
GG 2(0.041) 11(0.072)
rs2220972 G 102(1.000) 320(1.000)
GG 51(1.000) 160(1.000)
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Table 3 Allele and genotype frequencies in a case control cohort of patients with AS. (Continued)
rs1032551 C 30(0.306) 110(0.374) 0.2236 0.737968
(0.451984~1.204903)
G 68(0.694) 184(0.626)
CC 0(0.000) 13(0.088) 0.096659
CG 30(0.612) 84(0.571)
GG 19(0.388) 50(0.340)
rs34282382 A 102(1.000) 298(0.949) 0.020115
C 0(0.000) 6(0.051)
AA 51(1.000) 141(0.898) 0.017687 1 0.501138
AC 0(0.000) 16(0.102)
rs7840971 A 0(0.000) 1(0.003) 0.571929
G 102(1.000) 319(0.997)
AG 0(0.000) 1(0.006) 0.571472 1 0.968372
GG 51(1.000) 159(0.994)
rs7841304 A 0(0.000) 1(0.003) 0.576716
G 92(1.000) 295(0.997)
AG 0(0.000) 1(0.007) 0.576223 1 0.967107
GG 46(1.000) 147(0.993)
rs7818073 T 102(1.000) 320(1.000)
TT 51(1.000) 160(1.000)
rs7841425 A 15(0.153) 91(0.318) 0.001611 0.002234 0.01396 0.387263
(0.211775~0.708169}
C 83(0.847) 195(0.682)
AA 0(0.000) 17(0.119) 0.007879 0.005902 0.205909 0.330884
AC 15(0.306) 57(0.399)
CC 34(0.694) 69(0.483)
CI, confidence interval; HWE, Hardy-Weinberg equilibrium.


















P value after multiple
testing correction
(Bonferroni method)





















AA 91(0.350) 64(0.400) 0.506516 0.923195 0.185552
AG 125(0.481) 68(0.425)
GG 44(0.169) 28(0.175)




AG 4(0.015) 1(0.006) 0.412665 0.901484 0.968372
GG 261(0.985) 159
(0.994)
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Table 4 Allele and genotype frequencies in a case control cohort of patients with RA. (Continued)






AA 77(0.291) 55(0.346) 0.079064 0.86122 0.006761
AG 133(0.502) 62(0.390)
GG 55(0.208) 42(0.264)






















AA 122(0.496) 77(0.507) 0.238757 0.003729 0.641532
AG 115(0.467) 64(0.421)
GG 9(0.037) 11(0.072)
rs2220972 A 1(0.002) 0(0.000) 0.438632
G 533(0.998) 320
(1.000)
AG 1(0.004) 0(0.000) 0.438364 0.975544 1
GG 266(0.996) 160
(1.000)






















AG 2(0.008) 1(0.007) 0.887172 0.949269 0.967107
GG 247(0.992) 147
(0.993)
rs7818073 A 4(0.008) 0(0.000) 0.12006
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also significantly increased in the stimulated cells. Fol-
lowing treatment with 100 uM acetazolamide, the expres-
sion of CA1 was obviously decreased in the cells, and the
mRNA levels of ALP, BSP, OCN and Runx2 were drama-
tically decreased. Calcium nodule formation was also
decreased in the treated Saos-2 cells. The inhibitor did
not significantly reduce the cell proliferation. Thus, the
decrease in mineralization was due to a direct effect on
mineralization rather than decreased cell number. In
vitro experiments indicated that CA1 catalyzes the gen-
eration of HCO3
- through the hydration of CO2, which
then combines with Ca2+ to form a CaCO3 precipitate
[7,8]. Therefore, our study suggests that CA1 can pro-
mote the formation of calcium carbonate and calcifica-
tion under physiological conditions. Mineralization is a
key step for the formation, development, remodeling and
repair of the osseous tissue [18,19]. The over-expression
of CA1 very likely has an important role in ossification
and new bone formation.
By genotyping twenty-nine SNPs located in the CA1
region, Illumina microassay demonstrated a significant
association between rs34282382 and rs7841425 poly-
morphisms and susceptibility to AS in Chinese popula-
tions. Taqman genotyping confirmed the significant
association between the CA1 polymorphism and suscept-
ibility to AS risk. The above genotyping result suggests
that the gene encoding CA1 is susceptible to AS.
SNP rs34282382 is located in the 5’-UTR of the CA1
gene. The 5’UTR of mRNA plays a critical role in transla-
tion regulation by influencing mRNA stability and transla-
tion efficiency. Functional elements in the 5’-UTR such as
internal ribosome entry site (IRES), upstream ORF and
iron responsive element (IRE) serve to fine tune protein
expression in response to cellular requirements. Genetic
variations such as mutations and SNPs in the 5’-UTR are
associated with a number of human diseases and increased
susceptibility to diseases. Riboswitches are non-protein
coding RNA elements typically found in the 5’-UTR of
mRNAs that utilize metabolite binding to control expres-
sion of their own transcript. The RNA-ligand interaction
causes conformational changes in the RNA that direct the
cotranscriptional folding of a downstream secondary struc-
tural switch that interfaces with the expression machinery
[20]. We had detected the over-expression of CA1 in the
synovium of AS patients as compared with samples from
RA and OA. It increases the likelihood that elevated CA1
expression in AS synovial membrane may be a con-
sequence of up-regulation in sequence variation of
rs34282382 in 5’UTR.
The bone tissue is essentially composed of calcium and
phosphate precipitates, and calcium carbonate is only 10%
in mean of depositions [21]. Although there is no report
about the possible role of CA1 in pathophysiological bone
formation processes, CO3
2- ion was initially regarded as an
essential part of the calcium phosphate crystal complex.
Biltz et al. suggested that the synthesis of bone mineral
involves hydrolysis of an initial acidic calcium phosphate
precipitate to octacalcium phosphate, which is then con-
verted to octacalcium phosphate carbonate. Octacalcium
phosphate carbonate satisfies many criteria for a satisfac-
tory definition of the nature of the bone mineral [22].
Vuola et al. implanted blocks of natural coral (calcium
carbonate) and its structurally similar derivate in the form
of hydroxyapatite (calcium phosphate) in rat latissimus
dorsi muscle with autogenous bone marrow to compare
their bone-forming capability. They found that bone for-
mation was significantly higher in coral than in hydroxya-
patite implants [23]. Ripamonti et al. implanted rods and
discs (comprising 13% hydroxyapatite and 5% calcium car-
bonate constructs) into heterotopic rectus abdominis sites
and orthotopic calvarial defects of adult non-human pri-
mates, respectively. They found that partially converted
hydroxyapatite/calcium carbonate constructs induce spon-
taneous differentiation of bone [24]. The use of natural
coral as a bone graft substitute is common in orthopedic
surgery. Histological study detected in vivo formation of a
Table 4 Allele and genotype frequencies in a case control cohort of patients with RA. (Continued)
T 528(0.992) 320
(1.000)








AA 46(0.183)) 17(0.119) 0.250595 0.000748 0.330884
AC 92(0.365) 57(0.399)
CC 114(0.452) 69(0.483)
CI, confidence interval; HWE, Hardy-Weinberg equilibrium.
Chang et al. Arthritis Research & Therapy 2012, 14:R176
http://arthritis-research.com/content/14/4/R176
Page 12 of 14
calcium phosphate-rich layer on the surface of the coral
[25]. The above reports indicate that calcium carbonate is
involved in initial bone formation, although most mineral
deposits are not calcium carbonate but calcium phosphate.
Increased bone resorption is a characteristic of AS and
RA [26-29]. It has been found that carbonic anhydrase
activity enhanced the stimulation of prostaglandin E2 for
bone resorption [12]. Some groups found that the carbo-
nic anhydrase inhibitor acetazolamide inhibited bone
resorption [30,31]. They suggested that the carbonic anhy-
drase inhibitors played an antiarthritic role by inhibiting
bone resorption. In a case report, we have also reported
that methazolamide, an anti-CA drug, may improve AS
symptoms [32]. CA1 carries out the catalysis of the follow-




- but also hydrogen ion (H+). Hydrogen
ions are produced in the cytoplasm and are secreted extra-
cellularly by H+-ATPase, and the secreted hydrogen ion
dissolves bone mineral. Hence, CA1 may contribute to
bone resorption in AS and RA by producing hydrogen
ions, although the detailed mechanism of CA1 in the pro-
cesses is still unknown. In RA, focal bone loss is due to
excess bone resorption by osteoclasts. In contrast to RA,
inflammation in AS often results in excess periosteal bone
formation [33]. The present study demonstrated that CA1
had different SNPs associated with RA and AS, supporting
that CA1 plays different roles for bone resorption and
bone formation by mediating calcification.
Conclusions
In summary, the present study provided direct data to
support involvement of CA1 in calcification, a key step
for bone formation and bone remodeling. SNPs in the
CA1 encoding gene have a strong association with AS
and RA. The above finding may be helpful in understand-
ing the pathogenic mechanism of bone development in
RA and AS.
Additional material
Additional file 1: Genotyping result of Illumina SNP VeraCode
microarray. Genotyping was performed using Illumina VeraCode
microarray in a case-control study including 51 ankylosing spondylitis
(AS) patients, 267 rheumatoid arthritis (RA) patients and 160 health
controls.
Abbreviations
AA: ascorbic acid; ALP: alkaline phosphatase; ANOVA: analysis of variance;
AR-S: alizarin red; AS: ankylosing spondylitis; Β-GP: β-glycerophosphate; bp:
base pair; BSP: bone sialoprotein; CA1: carbonic anhydrase I; CCP: cyclic
citrullinated peptide; CI: confidence interval; Ct: comparative threshold cycle;
DMSO: dimethyl sulfoxide; HWE: Hardy-Weinberg equilibrium; IRES: internal
ribosome entry site; LD: linkage disequilibrium; OA: osteoarthritis; OCN:
osteocalcin; OM: osteogenic medium; OR: odds ratio; OSX: osterix; PBS:
phosphate-buffered saline; PCR: polymerase chain reaction; RA: rheumatoid
arthritis; RF: rheumatoid factor; Runx2: runt-related transcription factor-2; SNP:
single nucleotide polymorphism; UTR: untranslated region.
Acknowledgements
This study was supported by the National Natural Science Foundation of
China (NTFC) (30972720), the National Basic Research Program of China
(2010CB529105), Provincial Natural Science Foundation of Shandong
(ZR2010CM1032, Y2007C132, Y2008C130) and the Shandong Taishan
Scholarship.
Author details
1Medical Research Center of Shandong Qianfoshan Hospital, Shandong
University. Jingshi Road 16766, Jinan, Shandong, 250014 P. R. China.
2Shandong Academy of Medical Sciences. Jingshi Road 18877, Jinan,
Shandong, 250062 P. R. China. 3Department of Rheumatology, Provincial
Hospital of Shandong, Shandong University, Jingwuweiqi Road 324, Jinan,
Shandong, 250021 P. R. China. 4Orthopedic Surgery Center of Shandong
Qianfoshan Hospital, Shandong University, Jingshi Road 16766, Jinan,
Shandong, 250014 P. R. China.
Authors’ contributions
XC designed and executed the study and prepared the manuscript. YZ and
LW performed cell culture, western blotting and real time PCR. YX and JP
performed the genotyping. XY collected tissue samples. All authors have
read and approved the final manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 6 April 2012 Revised: 31 May 2012 Accepted: 27 July 2012
Published: 27 July 2012
References
1. Zhang X, Aubin JE, Inman RD: Molecular and cellular biology of new
bone formation: insights into the ankylosis of ankylosing spondylitis.
Curr Opin Rheumatol 2003, 15:387-393.
2. Schett G: Bone formation versus bone resorption in ankylosing
spondylitis. Adv Exp Med Biol 2009, 649:114-121.
3. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W,
Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P:
Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show
increased bone resorption, but differ with regard to bone formation.
J Rheumatol 2002, 29:1430-1436.
4. Chen WS, Chen CH, Lin KC, Tsai CY, Liao HT, Wang HB, Chen YK, Yang AH,
Chen TC, Chou CT: Immunohistological features of hip synovitis in
ankylosing spondylitis with advanced hip involvement. Scand J
Rheumatol 2009, 38:154-155.
5. Chang X, Han J, Zhao Y, Yan X, Sun S, Cui Y: Increased expression of
carbonic anhydrase I in the synovium of patients with ankylosing
spondylitis. BMC Musculoskelet Disord 2010, 11:279.
6. Supuran CT: Carbonic anhydrases–an overview. Curr Pharm Des 2008,
14:603-614.
7. Parissa M, Koorosh A, Nader M: Investigating the application of enzyme
carbonic anhydrase for CO2 sequestration purposes. Ind Eng Chem Res
2007, 46:921-926.
8. Ramanan R, Kannan K, Sivanesan SD, Ramanan R, Kannan K, Sivanesan SD,
Mudliar S, Kaur S, Tripathi AK, Chakrabarti T: Bio-sequestration of carbon
dioxide using carbonic anhydrase enzyme purified from Citrobacter
freundii. World J Microbiol Biotechnol 2009, 25:981-987.
9. Thouverey C, Strzelecka-Kiliszek A, Balcerzak M, Buchet R, Pikula S: Matrix
vesicles originate from apical membrane microvilli of mineralizing
osteoblast-like Saos-2 cells. J Cell Biochem 2009, 106:127-138.
10. Gregory CA, Gunn WG, Peister A, Prockop DJ: An Alizarin red-based assay
of mineralization by adherent cells in culture: comparison with
cetylpyridinium chloride extraction. Anal Biochem 2004, 329:77-84.
11. Heng NH, N’Guessan PD, Kleber BM, Bernimoulin JP, Pischon N: Enamel
matrix derivative induces connective tissue growth factor expression in
human osteoblastic cells. J Periodontol 2007, 78:2369-2379.
12. Hall GE, Kenny AD: Role of carbonic anhydrase in bone resorption
induced by prostaglandin E2 in vitro. Pharmacology 1985, 30:339-347.
Chang et al. Arthritis Research & Therapy 2012, 14:R176
http://arthritis-research.com/content/14/4/R176
Page 13 of 14
13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd,
Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B,
Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K,
Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA,
Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E,
Symmons D, et al: Rheumatoid arthritis classification criteria: an American
College of Rheumatology/European League Against Rheumatism
collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
14. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics 2005, 21:263-265.
15. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y: A partition-ligation-
combination-subdivision EM algorithm for haplotype inference with
multiallelic markers: update of the SHEsis. Cell Res 2009, 19:519-523.
16. Vaingankar SM, Fitzpatrick TA, Johnson K, Goding JW, Maurice M,
Terkeltaub R: Subcellular targeting and function of osteoblast nucleotide
pyrophosphatase phosphodiesterase 1. Am J Physiol Cell Physiol 2004, 286:
C1177-C1187.
17. Gillette JM, Nielsen-Preiss SM: The role of annexin 2 in osteoblastic
mineralization. J Cell Sci 2004, 117:441-449.
18. Thouverey C, Bleicher F, Bandorowicz-Pikula J: Extracellular ATP and its
effects on physiological and pathological mineralization. Curr Opin
Orthop 2007, 18:460-466.
19. Huitema LF, Vaandrager AB: What triggers cell-mediated mineralization?
Front Biosci 2007, 12:2631-2645.
20. Garst AD, Batey RT: A switch in time: detailing the life of a riboswitch.
Biochim Biophys Acta 2009, 1789:584-591.
21. Bonjour JP: Calcium and phosphate: a duet of ions playing for bone
health. J Am Coll Nutr 2011, 30:438S-448S.
22. Biltz RM, Pellegrino ED: The nature of bone carbonate. Clin Orthop Relat
Res 1977, 129:279-292.
23. Vuola J, Göransson H, Böhling T, Asko-Seljavaara S: Bone marrow induced
osteogenesis in hydroxyapatite and calcium carbonate implants.
Biomaterials 1996, 17:1761-1766.
24. Ripamonti U, Crooks J, Khoali L, Roden L: The induction of bone formation
by coral-derived calcium carbonate/hydroxyapatite constructs.
Biomaterials 2009, 30:1428-1439.
25. Damien CJ, Ricci JL, Christel P, Alexander H, Patat JL: Formation of a
calcium phosphate-rich layer on absorbable calcium carbonate bone
graft substitutes. Calcif Tissue Int 1994, 55:151-158.
26. Schett G: Bone formation versus bone resorption in ankylosing
spondylitis. Adv Exp Med Biol 2009, 649:114-121.
27. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W,
Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P:
Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show
increased bone resorption, but differ with regard to bone formation.
J Rheumatol 2002, 29:1430-1436.
28. Karmakar S, Kay J, Gravallese EM: Bone damage in rheumatoid arthritis:
mechanistic insights and approaches to prevention. Rheum Dis Clin North
Am 2010, 36:385-404.
29. Walsh NC, Gravallese EM: Bone remodeling in rheumatic disease: a
question of balance. Immunol Rev 2010, 233:301-312.
30. Hall GE, Kenny AD: Role of carbonic anhydrase in bone resorption: effect
of acetazolamide on basal and parathyroid hormone-induced bone
metabolism. Calcif Tissue Int 1987, 40:212-218.
31. Nolan JC, Gathright CE, Radvany CH, Barrett RJ, Sancilio LF: Carbonic
anhydrase inhibitors are antiarthritic in the rat. Pharmacol Res 1991,
24:377-383.
32. Chang X, Yan X, Zhang Y: Treat ankylosing spondylitis with
methazolamide. Int J Med Sci 2011, 8:413-419.
33. Walsh NC, Gravallese EM: Bone remodeling in rheumatic disease: a
question of balance. Immunol Rev 2010, 233:301-312.
doi:10.1186/ar3929
Cite this article as: Chang et al.: Carbonic anhydrase I (CA1) is involved
in the process of bone formation and is susceptible to ankylosing
spondylitis. Arthritis Research & Therapy 2012 14:R176.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chang et al. Arthritis Research & Therapy 2012, 14:R176
http://arthritis-research.com/content/14/4/R176
Page 14 of 14
